TLR7 antagonist-1

TLR7 antagonist-1 (Compound 44#) 是一种具有口服活性的选择性 TLR7 拮抗剂,对 TLR7 的 IC50 值为 0.3 nM,可选择性结合 TLR7 并抑制其活化、下调 c-Rel 信号通路,同时下调促炎细胞因子 IL-1β、IL-6、TNF-α 的 mRNA 水平,减轻 Imiquimod (MS-W79117) 诱导的银屑病样皮损,可用于银屑病的相关研究。
产品编号: MS-O70930 CAS No.: 3104353-70-7 分子式: C21H25ClF3N5O 分子量: 455.90
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TLR7 antagonist-1 (Compound 44#) 是一种具有口服活性的选择性 TLR7 拮抗剂,对 TLR7 的 IC50 值为 0.3 nM,可选择性结合 TLR7 并抑制其活化、下调 c-Rel 信号通路,同时下调促炎细胞因子 IL-1β、IL-6、TNF-α 的 mRNA 水平,减轻 Imiquimod (MS-W79117) 诱导的银屑病样皮损,可用于银屑病的相关研究。

生物实验数据

生物活性 TLR7 antagonist-1 (Compound 44#) is an orally active and selective TLR7 antagonist with an IC50 value of 0.3 nM against TLR7 that selectively binds to TLR7, inhibits its activation, downregulates the c-Rel signaling pathway, reduces the mRNA levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, alleviates Imiquimod (MS-W79117)-induced psoriasis-like skin lesions, and can be used for research related to psoriasis.
IC50 & Target TLR7:0.3 nM
体外研究
(In Vitro)

TLR7 antagonist-1 可在 HEK-Blue-HTLR7 细胞中强效且选择性地抑制 TLR7,其 IC50 为 0.3 nM,对 TLR8 和 TLR9 的活性则弱得多。
TLR7 antagonist-1 (0.005-5 μM; 12 h) 可浓度依赖性地抑制 RAW264.7 和 HEK-Blue-HTLR7 细胞中 TLR7 介导的炎性细胞因子。

Real Time qPCR

Cell Line: RAW264.7 cells, HEK-Blue-HTLR7 cells
Concentration: 0.005-5 μM (RAW264.7 cells); 0.005-5 μM (HEK-Blue-HTLR7 cells)
Incubation Time: 12 h
Result: Concentration-dependently downregulated R848-induced mRNA levels of IL-1β, IL-6, TNF-α in RAW264.7 cells.
Concentration-dependently reduced IFN-α mRNA levels in HEK-Blue-HTLR7 cells, with 0.5 μM showing better efficacy than 5 μM Enpatoran (MS-F00665).
体内研究
(In Vivo)

TLR7 antagonist-1 (15-45 mg/kg;口服) 可有效缓解雌性 BALB/C 小鼠中 Imiquimod (MS-W79117) 诱导的银屑病样皮肤炎症、全身免疫应答及相关肝肾功能损伤,且炎症标志物水平和组织损伤程度呈剂量依赖性降低。

Animal Model: BALB/C (female, 6 weeks old, 15-16 g, imiquimod-induced psoriasis-like dermatitis)
Dosage: 15 mg/kg; 45 mg/kg
Administration: p.o.
Result: Reduced PASI scores significantly compared to the model group, with only slight skin thickening appearing from day 18.
Reduced epidermis/stratum corneum thickening, Munro microabscesses, and subdermal lymphocyte infiltration compared to the model group, with dermis and cuticle thickness near control levels.
Reversed spleen enlargement, with spleen weights near control levels.
Reduced mRNA levels of NF-κB p65 and c-Rel in skin tissue in a dose-dependent manner, with high-dose group c-Rel levels comparable to control group.
Reduced serum and skin tissue levels of inflammatory cytokines IL-17A and IL-1β in a dose-dependent manner.
Normalized elevated white blood cell counts, lymphocyte counts, and lymphocyte percentages in the model group to control levels.
Reduced model group increases in ALT, AST, BUN, and Scr in a dose-dependent manner, with high-dose group showing the most significant liver and renal function protection.
Showed no significant differences in body weight, liver/kidney weight, or histopathological damage to liver, kidney, or spleen across groups.

化学信息

分子量 455.90
分子式 C21H25ClF3N5O
CAS No. 3104353-70-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础